Biotech Values

[DewDiligence]

Re: BMY I-O counterpoint

I'm apparently more bullish than most investors on BMY's I-O prospects. Some positives: i) Opdivo approvals in >15 cancer types (some of which are too recent to have had an impact on sales); ii) the NKTR-214 collaboration (which includes 35% ownership of NKTR-214 per se); and iii) Opdivo/Yervoy—without chemo—has shown a survival benefit in melanoma and RCC, so it's not an enormous stretch to think this combination could eventually have a place in a subgroup of NSCLC.